FTH1P25

Across TCGA pan-cancer cohorts, FTH1P25 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of FTH1P25’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where FTH1P25 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FTH1P25 is over-expressed in tumor.

KIRC, BLCA, and THCA are the cancer types where FTH1P25 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FTH1P25 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.078	.001	8	view →
BLCA	Female	All	+0.169	.014	3	view →
THCA	All	III,IV	+0.091	.019	3	view →
BRCA	Female	All	+0.141	.043	2	view →
COAD	Female	IV	+0.365	.001	1	view →
LUAD	All	All	+0.207	.036	1	view →
STAD	Male	II,III,IV	+0.081	.020	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

FTH1P25–KIRC

Open the KIRC breakdown →